Advantage Alpha Capital Partners LP Alkermes Plc. Transaction History
Advantage Alpha Capital Partners LP
- $515 Million
- Q1 2024
A detailed history of Advantage Alpha Capital Partners LP transactions in Alkermes Plc. stock. As of the latest transaction made, Advantage Alpha Capital Partners LP holds 39,008 shares of ALKS stock, worth $943,603. This represents 0.2% of its overall portfolio holdings.
Number of Shares
39,008
Previous 49,530
21.24%
Holding current value
$943,603
Previous $1.37 Million
23.16%
% of portfolio
0.2%
Previous 0.26%
Shares
2 transactions
Others Institutions Holding ALKS
# of Institutions
357Shares Held
180MCall Options Held
522KPut Options Held
463K-
Black Rock Inc. New York, NY29.2MShares$706 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA20.2MShares$488 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA14.9MShares$360 Million0.07% of portfolio
-
State Street Corp Boston, MA9MShares$218 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD8.33MShares$201 Million0.03% of portfolio
About Alkermes plc.
- Ticker ALKS
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 164,254,000
- Market Cap $3.97B
- Description
- Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...